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Introduction
Dermatofibrosarcoma protruberans (DP) is a rare, low –
grade sarcoma infiltrating the skin, with aggressive local
growth and high local recurrence potential. Wide surgical
excision of the tumor is the best method of treatment.
A small percentage of patients (approximately <5%)
may develop metastatic disease, mainly to the lungs,
lymph nodes and bones. In the case of dissemination,
the prognosis of the majority of patients is almost always
fatal and similar to the other soft tissue sarcomas,
although the progression is usually slow and lasting
several years [1-5]. In metastatic disease there are not
any established, standard treatment modalities.
Imatinib mesylate is a new-generation antineoplastic
agent with tyrosin-kinase inhibitor activity. Imatinib has
been shown to have impressive efficiency in CML
(chronic myeloid leukemia) and GIST (gastrointestinal
stromal tumor) treatment, targeting Bcr-Abl and c-KIT
receptors, respectively. Imatinib in vivo has also shown
activity against PDGF-driven tumor models including
glioblastoma, DP (dermatofibrosarcoma protuberans)
and chronic myelomonocytic leukemia [6, 7].
Till now three cases of patients with advanced DP
treated with imatinib mesylate have been published, with
satisfactory results reported in two of them [8, 9]. The
aim of our report is to present partial response of lung
metastases during imatinib mesylate therapy in a patient
with DP.
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We report the case of a 36 year old woman with multiple reccurent dermatofibrosarcoma lung metastases, who was primary
treated surgically (multiple metastases resection) and with different chemotherapy regimens, who finally demonstrated
progressive unresectable disease. The patient was experimentally treated with tyrosine kinase inhibitor imatinib mesylate
(400 mg once daily). After one month of treatment the patient demonstrates partial regression (PR) of lung metastases
according to RECIST criteria (total tumor dimensions decreased by over 30%). This case demonstrates the activity of a new
small molecule inhibitor – imatinib mesylate – in the treatment of metatastatic dermatofibrosarcoma, probably by the
inhibition of the platelet-derived growth factor β (PDGFβ) receptor.
Cz´Êciowa regresja przerzutów do p∏uc u chorej na dermatofibrosarcoma protuberans
po miesiàcu leczenia imatinibem mesylate – opis przypadku
W pracy przedstawiono przypadek 36 letniej chorej na dermatofibrosarcoma z przerzutami do p∏uc leczonej kilkukrotnymi
resekcjami, ró˝nymi schematami chemioterapii i u której ostatecznie stwierdzono nieoperacyjne przerzuty do p∏uc z cechami
progresji nie dajàcej si´ opanowaç leczeniem przeciwnowotworowym. U chorej rozpocz´to leczenie inhibitorem kinazy
tyrozynowej – imatinibem w dawce 400 mg 1 raz dziennie. Po miesiàcu leczenia stwierdzono cz´Êciowà remisj´ (PR) zmian
przerzutowych w p∏ucach ocenionà zgodnie z kryteriami RECIST (zmniejszenie sumy najd∏u˝szych wymiarów zmian o wi´cej
ni˝ 30%). Prezentowany przypadek wskazuje na aktywnoÊç nowego leku przeciwnowotworowego – imatinibu w leczeniu
przerzutowego dermatofibrosarcoma, prawdopodobnie w mechanizmie blokowania receptora dla p∏ytkowopochodnego
czynnika wzrostu β (PDGFRβ).
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Patient and methods
A Thirty year old (b. 1966) female patient was seen first time at
the Department of Soft Tissue/Bone Sarcoma and Melanoma in
November 1996. She was referred because of lung metastases
which were found accidentally on a chest X-ray performed
3 years after primary tumor excision.
The excision of the primary tumor located in the left
subscapular region was performed under local aneaesthesia in
a county hospital outpatient clinic in October 1993. The
postoperative pathology report revealed dermatofibrosarcoma
protuberans (DP). The diagnosis was confirmed by two
independent pathologists. Over a year later she was re-operated
on because of local recurrence in the subcutaneous part of the
scar and subsequently, second pathologic examination confirmed
the diagnosis of dermatofibrosarcoma. However, at that time,
fibrosarcomatous areas were found within the specimen. On
this basis the surgeon decided to extend the excision and to use
the thin skin graft to cover the ample tissue defect. 18 months
later, without any clinical symptoms, lung metastases were
detected on accidentally performed chest radiograms. On first
admission to our Department in November 1996, additional
diagnostic investigations did not disclose any other abnormalities,
except lung metastases. Ifosfamide in monotherapy was decided
on and introduced as systemic treatment. During the next
5 years, i.e. from November 1996 to June 2001, the patient was
treated by three different chemotherapy regimens and
underwent three subsequent thoracotomies because of recurrent
lung metastases. The treatment details are shown in Table I.
Histologic findings after each thoracotomy demonstrated
the presence of lung metastases with viable sarcoma cells
and the diagnosis of metastatic dermatofibrosarcoma was
confirmed. In last exam (i.e. after third thoracotomy performed
in February 2001), immunohistochemical staining was positive
for CD34 and negative for CD117. Unfortunately, after the next
fifteen months of follow-up fourth recurrence (two bilateral
lung metastatic lesions) was revealed. The patient did not
undergo subsequent thoracotomy because her lung function
tests (FVC – forced vital capacity and FEV1 – forced expiratory
volume in one second) were on bordeline values. Palliative care
and the best supportive treatment (cyclophosphamide,
etoposide, ketoprofen, ranitidine, allopurinol) were introduced.
The evident progression of lung metastases was noted at the
end of October 2002.
The repeated pathology examination of paraffin-embedded
tissue from metastasis removed during last thoracotomy (in
February, 2001) has confirmed immunohistochemical staining
positive for CD34 and negative for CD117.
Taking into account her young age, WHO performance
status "0" and based on data from literature she was offered
to be treated with imatinib mesylate (Glivec®), Gleevec™) [8, 9].
It was decided to start therapy with 400 mg per day orally
with the possibility of dose enlargement, if necessary, up to
800 mg daily (400 mg twice daily). Informed consent was
obtained.
For assessment of the objective response to the treatment,
the longest diameters of both lung metastases measured on
plain chest X-ray, were chosen. In the meantime, supportive
treatment was ceased at the beginning of November 2002 to
maintain at least a 30 day treatment-free interval before
introducing imatinib.
Results
At first measurable features of progression in the last
several weeks before imatinib therapy introduction were
calculated. During the three weeks of follow-up both
pulmonary metastatic lesions were evidently enlarged;
the right metastatic nodule from 42 mm to 51 mm (21%,
9/42mm) and the left supraphrenic tumor from 25 to 27
mm (8%, 2/25) (Table II, Figure 1A and 1B). Altogether
the features of progression could be expressed as 16%
(11/67).
Table II. Results of measurements of metastatic lung metastases
date right nodule left nodule total comment
25/11/02 42 mm 25 mm 67 mm
18/12/02* 51 mm 27 mm 78 mm progression
20/01/03 35 mm 17 mm 52 mm partial response
*) – first day of therapy with imatinib 400 mg daily
Imatinib therapy was introduced on December 18,
2002. After 31 days of treatment the largest diameter of
bigger nodule decreased to 35 mm, (i.e. by 31% of
Table I. Summary of treatment decision details
date event comments
10/1993 local excision first operation of DP located in left subscapular region
01/1995 re-excision second operation for local recurrence
02/1995 re-excision third operation – wider excision of scar with thin skin graft
09/1996 chest X-ray, CT lung metastases
11/1996 chemotherapy ifosfamide, partial response (PR)
08/1997 sternotomy bilateral metastasectomy (two tumors)
06-10/1998 chest X-ray, CT new lung metastases with slow progression during follow-up
11/1998 chemotherapy doxorubicin, dacarbazine, four courses, partial response
03/1999 right thoracotomy metastasectomy (three tumors)
03-06/1999 chemotherapy doxorubicin, dacarbazine, four courses postoperatively
08-10/2000 chest X-ray, CT the third recurrence of metastasis, right lung solitary with slow progression during follow-up
11/2000 chemotherapy doxorubicin, cis-platin; vepesid cis-platin, stable disease
02/2001 right re-thoracotomy metastasectomy (one tumor)
03-06/2001 chemotherapy vepesid, cis-platin, six courses postoperatively
05/2002 chest X-ray the fourth recurrence, bilateral lung metastases
06-11/2002 chest X-rays paliative therapy, slow progression of lung metastases
18/12/2002 chemotherapy imatinib mesylate 400 mg p.o. daily
20/01/2003 chest X-ray partial response (PR)
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previous size), and the longest diameter of the smaller
lesion decreased to 17 mm (corresponding to a 37%
response) (Figure 1B and 1C). The summed up diameters
of both target lesions decreased to 52 mm i.e. a 33%
reduction of baseline diameter (Table II). No new lesions
were observed (Figure 1C). According to RECIST criteria
it could be defined as the partial response (PR).
No toxicity nor other significant adverse events of
imatinib therapy were observed.
Discussion
Imatinib mesylate is an inhibitor of tyrosine kinases
including Bcr-Abl (responsible for CML), c-KIT (re-
sponsible for GIST) and PDGFβ receptors. The
mechanism of the reduction of metastases in our patient
is unclear. Inhibition through the Kit signaling pathway is
questionable, because CD117 (for c-KIT cell surface
receptor) immunohistochemistry examination was
negative. Alternatively, the treatment effect of imatinib
might be due to another target connected with the
PDGFβ receptor. It has been determined that DP cells in
culture show greater response to PDGF(BB) than normal
fibroblasts, as well as showing an upregulation of PDGFβ
receptor revealed by binding assay and immunoblotting
analysis. This suggests that blocking the overexpression of
the PDGFβ receptor might play a role in the inhibition of
progression of DP lung metastases in this patient [10].
Imatinib probably has also antiangiogenic activity. The
inhibition of PDGF-, VEGF- and bFGF-stimulated
vascularization of mouse subcutaneous implants by
Figure 1A Figure 1B
Figure 1C
Figure 1 – Plain chest X-rays
A – Three weeks before treatment start – on 25 November, 2002
B – At the day of treatment beginning – on 18 December, 2002
C – One month after imatinib therapy – on 20 January, 2003
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imatinib was shown on in vitro and in vivo models of
assays for growth factor-induced angiogenesis. These
results suggest, that imatinib in vivo may inhibit not only
endothelial cell activation (by VEGF and bFGF) but
smooth muscle cells or pericytes, as well. This could
prevent the stabilization both of tumor capillaries and
bigger vessels in the tumor [6].
It is worth mentioning that the other DP-like family
of tumors, apart from classic dermatofibrosarcoma
protuberans, includes: giant cell fibroblastoma (juvenile
analogue of DP), Bednar tumor (pigmented variant of
DP) and possibly, superficial adult fibrosarcoma
(equivalent of fibrosarcomatous transformation of DP).
The common feature of all these tumors is the expression
of the COL1A1-PDGFB chimeric gene resulting from
a reciprocal translocation, t(17;22), and/or (in adults)
supernumerary ring chromosome, r(17:22). What is more
interesting, the fibrosarcomatous areas of primary and
metastatic tumors may maintain positive immuno-
histochemistry staining for CD34 [1, 11-18].
Because of the uncertain effect of imatinib therapy in
dermatofibrosarcoma, we decided to choose a treatment
regimen proposed in the protocol of EORTC 62005 trial
for GIST treatment: the basic imatinib dose of 400 mg
daily and, if not effective, increase drug dose up to 800 mg
daily. In this case, a partial response was achieved after
400 mg daily of imatinib dosage. The case report is the
first Polish patient description of impressive response of
metastatic dermatofibrosarcoma to imatinib mesylate
therapy.
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